歌禮制藥-B(01672.HK):上海市公共衞生臨牀中心在第12屆國際艾滋病協會HIV科學會議公佈ASC22(恩沃利單抗)聯合西達本胺用於HIV感染功能性治癒的臨牀結果
格隆匯7月25日丨歌禮制藥-B(01672.HK)發佈公吿,上海市公共衞生臨牀中心在澳大利亞布里斯班及線上舉行的第12屆國際艾滋病協會HIV科學會議上公佈ASC22(恩沃利單抗)聯合西達本胺用於人類免疫缺陷病毒(HIV)感染功能性治癒的臨牀結果。
這項研究者發起的II期試驗(ClinicalTrials.gov:NCT05129189)由上海市公共衞生臨牀中心感染與免疫科副主任醫師陳軍博士領導,共入組了15名已實現病毒學抑制的HIV感染者。在為期12周的治療中,受試者每4周進行皮下注射一次ASC22(1毫克 ╱ 千克),並聯合每週兩次口服10毫克西達本胺,同時維持抗逆轉錄病毒治療(ART)。受試者接受24周隨訪,並檢測細胞相關HIV RNA、血漿HIV RNA、總HIV DNA和整合HIV DNA以及HIV特異性CD8+ T細胞功能水平變化。
該研究旨在評估ASC22(恩沃利單抗)聯合西達本胺在HIV感染者中對被感染的潛伏期細胞病毒儲存庫的療效。歌禮生物科技(杭州)有限公司(公司的全資附屬公司)提供本次臨牀試驗的ASC22(恩沃利單抗)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.